Iran Press/ Iran news: In an interview with Iran Press on the sidelines of the ceremony of phase I of the clinical trial of the Iranian Fakhra coronavirus vaccine on Tuesday, Karimi said: "After the first phase of the clinical trial, we will have the second and third phases, after which the production of the vaccine will be allowed."
"Construction of a mass-production factory of the vaccine has started," he said, hoping that if the clinical results were confirmed, the fourth Iranian COVID-19 vaccine, dubbed as FAKHRAVAC (MIVAC) 19, would enter the mass production phase by the beginning of summer and that the clinical phases would be completed successfully.
Regarding the production capacity of the vaccine, the official added: "Considering the current infrastructure, we have the ability to produce 200,000 doses per month, and we hope to increase the production capacity to one million doses per month by then."
The clinical trial of the fourth Iranian COVID-19 vaccine, dubbed as FAKHRAVAC (MIVAC) 19, kicked off on Tuesday with the attendance of Defense Minister Brigadier General Amir Hatami and Health Minister Saeed Namaki by injecting to the first volunteer.
The volunteer was the son of Martyr Mohsen Fakhrizadeh, the head of the Iranian Defense Ministry’s Organization of Defensive Innovation and Research, which developed the vaccine.
Mohsen Fakhrizadeh, the Head of the Iranian Defense Ministry’s Organization of Defensive Innovation and Research, was targeted in a multi-pronged terrorist attack by several assailants in the Absard, Tehran Province Damavand County on November 27, 2020.
By Mojtaba Darabi
207/214
Read More:
Iranian Fakhra COVID-19 vaccine clinical trial started
